Rapid improvement of pyoderma gangrenosum after treatment with infliximab
Chan, J.L.; Graves, M.S.; Cockerell, C.J.; Pandya, A.G.
Journal of Drugs in Dermatology Jdd 9(6): 702-704
2010
ISSN/ISBN: 1545-9616 PMID: 20645536 Document Number: 14520
Infliximab, a novel chimeric anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.
Document emailed within 1 workday
